When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug

Shares of Revolution Medicines are trading higher Thursday morning as a wave of Wall Street firms issued price target increases following the commercial rollout of the company's first-in-class oncology therapy.

Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.

Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.

Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.

SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of $(0.07) per share

SELLAS Says Arbitrator Dismisses Its Claims Against 3D Medicines, Orders SELLAS To Pay Approximately $1M In Legal Fees

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001390478/000110465926087110/tm2621415d1_8k.htm